A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Clinical trial NCT07060807 · RECRUITING

Trial details

NCT number: NCT07060807
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2025-07-21
Primary completion: 2033-07-14
Enrollment: 1000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.